Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SUPERGLASS HOLDINGS PLC. We currently have 8 research reports from 1 professional analysts.
|21Sep16 10:13||RNS||Holding(s) in Company|
|16Sep16 05:05||RNS||Holding(s) in Company|
|15Sep16 12:14||RNS||Holding(s) in Company|
|15Sep16 12:11||RNS||Holding(s) in Company|
|15Sep16 12:08||RNS||Holding(s) in Company|
|02Sep16 04:26||RNS||Holding(s) in Company|
|31Aug16 07:05||RNS||Intention to delist and Board changes|
Frequency of research reports
Research reports on
SUPERGLASS HOLDINGS PLC
SUPERGLASS HOLDINGS PLC
Interim results in line; Turnaround plan on track
29 Apr 16
As flagged in the March trading update, this morning’s interim results are in line with expectations. After reducing losses at the adj. LBITDA level in the first half (£1.4m YoY upswing to deliver a loss of £0.5m), the Group is on track to deliver positive EBITDA for the first full year since 2012, a significant improvement. After a planned shift in the customer and product mix, revenue growth of 2% supported this result. The Group has made solid progress in implementing its ongoing turnaround plan, with the delivery of a 9% YoY reduction in production costs per tonne and a 22% YoY reduction in distribution costs per tonne. We have tweaked our forecasts this morning, with current year EBITDA now expected to be £0.8m from £1.0m and FY’17 EBITDA expected to be £2.2m from £2.6m as further expected cost savings and production efficiencies broadly offset a reduction in our revenue forecast. The outlook for Superglass is positive, with further improvements in the product and customer mix, and further cost savings expected.
Trading in line at half year end
10 Mar 16
Superglass’ trading update this morning confirms that the Group is trading in line with expectations at the half year stage. An H116 EBITDA loss of £0.5m is a marked improvement on the prior year and similar to the H215 outturn (£0.4m), which is a seasonally slower period given the Christmas break. Cost saving initiatives and production efficiencies are having the desired effect and the business mix has, again, improved. The Group is on track to deliver positive EBITDA for the current financial year as a whole and continues to trade with adequate cash headroom (£2.4m gross cash at the February period end).
Trading in line, more pricing improvements to come
19 Nov 15
Superglass’ FY15 results are in line with expectations. H2’15 saw a significant improvement in EBITDA (£0.4m adjusted loss versus £1.9m adjusted loss in H1). This bodes well for FY16 and, encouragingly, guidance is maintained. The new year stands to benefit from new product introductions, ongoing cost initiatives and another price increase in February. Management’s focus is now very much on margin improvement and cash generation rather than volume, which should support the transition to profitability over the forecast period after the challenges of recent years.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
16 Jan 17
We take a look at the rankings of the various countries in Africa that have a significant exposure to mining. We take the Transparency International corruption rankings as our starting point and modify these for exceptional geology and for current UK government travel warnings. Ghana, Botswana and Namibia come out as our top three, with Eritrea, Kenya and Zimbabwe at the bottom of our rankings.
19 Jan 17
Aggregated Micro Power* (AMPH): Funding for first peaking power plant project (CORP) | The Mission Marketing Group* (TMMG): Positive trading update (CORP) | Cello (CLL): Increasingly backed by, and leveraging, technology (BUY) | 4imprint (FOUR): Growth backed by strong cash flow continues (BUY) | Allergy Therapeutics (AGY): Positive trading update and market share gains drive upgrades (BUY) | Shanta Gold (SHG): Q4 operating results (BUY) | Sound Energy (SOU): Tendrara extended well test result (BUY) | Revolution Bars (RBG): Price target increase (BUY)
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - St Ives - Downgrade
19 Jan 17
Marketing activation has been impacted by further decline in grocery retail impacting profit by c£5m. Strategic The Company is also taking this opportunity to revise its guidance for Strategic Marketing as its recovery pace is not running at the planned target rate. PBT falls from N1Se £31.9m to £25m. The Company expects dividend to be held based upon lowered guidance and the implied cash flow performance. There do not appear to be any covenant issues. Forecasts and TP under review and downgrade to Hold. We expect the shares to test the 100p level.
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.